Table 2.
Treatments Received at or after Enrollment
| Characteristic | Itraconazole (N=32) | Standard Care (N=33) | Total (N=65) |
|---|---|---|---|
| Medication received during hospitalization | |||
| Hydroxychloroquine – no. (%) | 32 (100%) | 32 (97%) | 64 (99%) |
| Remdesivir – no. (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Antibiotics – no. (%) | 31 (97%) | 31 (97%) | 62 (95%) |
| Corticosteroids – no. (%) | 6 (19%) | 6 (18 %) | 12 (19%) |
| Tocilizumab – no. (%) | 0 (0%) | 1 (3%) | 1 (2%) |
| Admission to ICU – no. (%) | 10 (31%) | 9 (27%) | 19 (29%) |
| Respiratory support | |||
| Oxygen support – no. (%) | 29 (91%) | 29 (88%) | 58 (89%) |
| High-flow oxygen – no. (%) | 11 (34%) | 8 (24%) | 19 (29%) |
| Invasive mechanical ventilation – no. (%) | 6 (19%) | 5 (15%) | 11 (17%) |
| ECMO – no. (%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Renal replacement therapy – no. (%) | 1 (3%) | 1 (3%) | 2 (3%) |
ICU denotes intensive care unit, ECMO extracorporeal membrane oxygenation